Arvinas (ARVN) EBT Growth (1y) (2018 - 2026)
Powered by 
Analysis
Arvinas (ARVN) EBT Growth (1y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 8.48% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 0.60% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 88.92% |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 6.23% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 213.87% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 530.43% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -12.04% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 96.45% |
| 10 | Arvinas | 609.44 Mn | 41.54 Mn | - | 375.77% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 375.77% |
| Mar 31, 2026 | -169.19% |
| Dec 31, 2025 | -47.69% |
| Sep 30, 2025 | 28.40% |
| Jun 30, 2025 | -75.71% |
| Mar 31, 2025 | 219.91% |
| Dec 31, 2024 | 70.30% |
| Sep 30, 2024 | 23.94% |
| Jun 30, 2024 | 46.65% |
| Mar 31, 2024 | 14.66% |
| Dec 31, 2023 | -121.07% |
| Sep 30, 2023 | -4.58% |
| Jun 30, 2023 | -2.34% |
| Mar 31, 2023 | -43.46% |
| Dec 31, 2022 | -50.33% |
| Sep 30, 2022 | -30.56% |
| Jun 30, 2022 | -27.44% |
| Mar 31, 2022 | -38.05% |
| Dec 31, 2021 | -18.90% |
| Sep 30, 2021 | -51.14% |